<DOC>
	<DOCNO>NCT01051687</DOCNO>
	<brief_summary>Background : New light shed cholinergic aspect vitiligo pathophysiology . It find acetylcholine concentration increase significantly reduce expression acetylcholinesterase vitiliginous patch return normal repigmentation . Objective : The investigator undertake control , prospective pilot study evaluate efficacy safety botulinum toxin A patient localized vitiligo . Methods : 10 patient focal segmental vitiligo recruit . For patient focal vitiligo , one two vitiliginous patch treat . The patch use control . For patient segmental vitiligo , half lesion treat . The half use control . Botulinum toxin inject . The response analyze initial visit , two week two six month therapy .</brief_summary>
	<brief_title>Botulinum Toxin Treatment Localized Vitiligo</brief_title>
	<detailed_description>While perform botulinum toxin A ( BTX-A ) treatment glabellar frown line crow 's foot lady also periocular vitiligo , note gradual complete resolution vitiliginous patch , within month , without add therapy . To test observation , whether BTX-A lead repigmentation spontaneous one , design control , prospective pilot study evaluate efficacy safety BTX-A patient localize vitiligo . MATERIAL AND METHODS Patients The study conduct dermatology clinic King Khalid University Hospital . 10 patient focal segmental vitiligo recruit study Data collect patient interview include : patient characteristic ( age , sex , age onset vitiligo , disease activity , presence pruritus ) , medical history , previous treatment modality include clinical outcome modality . Complete physical examination laboratory test include : complete blood count , fast blood sugar thyroid autoantibody perform . Injection Procedure Dilution 1 ml unpreserved saline per 100 U vial BOTOX ( Allergen pharmaceutical , Irvine , CA ) . 2 unit inject intradermally every 1 cm2 1ml syringe 30 gauge needle . No treatment modality perform study . Assessments For patient focal vitiligo , one vitiliginous patch - two patch different sites- treat . The patch contra lateral site leave untreated used control follow-up visit . For patient segmental vitiligo , half lesion treat . The half leave untreated used control follow-up visit . The main outcome percentage repigmentation previously depigmented patch , form color size change folliculocentric repigmentation , treat control patch . Each patient assess three investigator injection BTX-A . Patients ; re-examined 2 wk , 2 6 month therapy . The outcome visit note standardized sheet . Standardized photograph treat control patch , include measurement , take visit . Repigmentation previously depigmented patch judge photograph measurement lesion compare pre treatment status blind dermatologist .</detailed_description>
	<mesh_term>Vitiligo</mesh_term>
	<mesh_term>Botulinum Toxins , Type A</mesh_term>
	<mesh_term>incobotulinumtoxinA</mesh_term>
	<mesh_term>abobotulinumtoxinA</mesh_term>
	<mesh_term>onabotulinumtoxinA</mesh_term>
	<mesh_term>Botulinum Toxins</mesh_term>
	<criteria>focal vitiligo segmental vitiligo receive treatment last 4 week patient contra indication BTXA</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>January 2010</verification_date>
	<keyword>vitiligo</keyword>
</DOC>